Bulk Inquiry
WZ 4002
- Soluble in 0.1N HCl(aq) and DMSO
- MF: C25H27ClN6O3
- MW: 494.97
Description
More Information
| Parent CAS No. | 1213269-23-8 |
|---|---|
| Chemical Name | N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazine-1-yl)phenylamino)pyrimidin-4yloxy)phenyl)acrylam |
| SMILES | C(=O)(NC1=CC=CC(OC2N=C(NC3=C(OC)C=C(C=C3)N3CCN(C)CC3)N=CC=2Cl)=C1)C=C |
| MFCD | MFCD16621244 |
| InChi | InChI=1S/C25H27ClN6O3/c1-4-23(33)28-17-6-5-7-19(14-17)35-24-20(26)16-27-25(30-24)29-21-9-8-18(15-22(21)34-3)32-12-10-31(2)11-13-32/h4-9,14-16H,1,10-13H2,2-3H3,(H,28,33)(H,27,29,30) |
| InChiKey | ITTRLTNMFYIYPA-UHFFFAOYSA-N |
| CID | 44607530 |
| Short Description | EGFR T790M inhibitor |
References
- W Zhou et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462, 1070-1074.
- Y Sakuma et al. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors. Laboratory Investigation 2012, 92, 371-383.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1128 | Erlotinib hydrochloride |
From $77.00 |
| 1357 | SD 169 |
From $66.00 |
| 1358 | BIRB 796 |
From $71.50 |
| 1363 | SB 203580 |
From $104.50 |
| 1364 | SB 202190 |
From $104.50 |
| 1365 | PD169316 |
From $104.50 |
| 1393 | Gefitinib |
From $77.00 |
| 1395 | Lapatinib ditosylate |
From $88.00 |
| 1398 | Sunitinib malate |
From $88.00 |
| 1411 | Vandetanib |
From $55.00 |
| 1414 | AG 013736 |
From $55.00 |
| 1420 | Pazopanib hydrochloride |
From $66.00 |
| 1433 | CI 1033 |
From $66.00 |
| 1461 | Cediranib |
From $77.00 |
| 1526 | Neratinib |
From $88.00 |
| 1544 | BIBW 2992 |
From $55.00 |
| 1547 | OSI 930 |
From $99.00 |
| 1632 | OSI 420 |
From $99.00 |
| 1637 | Vatalanib |
From $82.50 |
| 1638 | ABT 869 |
From $88.00 |
| 1653 | AEE 788 |
From $88.00 |
| 1662 | CP 547632 |
From $77.00 |
| 1665 | Pelitinib |
From $99.00 |
| 1667 | SU 5402 |
From $66.00 |
